Top

Published in:

01-04-2016 | Original Research

Newborn Screening for Lysosomal Storage Disorders: Views of Genetic Healthcare Providers

Authors: Emily C. Lisi, Shawn E. McCandless

Published in: Journal of Genetic Counseling | Issue 2/2016

Abstract

Lysosomal storage diseases (LSDs), lysosomal enzyme deficiencies causing multi-system organ damage, have come to the forefront in newborn screening (NBS) initiatives due to new screening technologies and emerging treatments. We developed a qualitative discussion tool to explore opinions of genetic healthcare providers (HCPs) regarding population-based NBS for MPS types 1 and 2, Pompe, Gaucher, Fabry, and Krabbe diseases. Thirty-eight telephone interviews conducted by a single researcher were analyzed and coded for thematic trends. Six major themes emerged: 1) treatment availability and efficacy is crucial; 2) early age of disease onset is important; 3) ambiguity regarding prognosis is undesirable; 4) parents’ ability to make reproductive decisions is seen by some as a benefit of NBS; 5) paucity of resources for follow-up exists; and 6) the decision-making process for adding conditions to mandated NBS is concerning to HCPs. Among the LSDs discussed, Pompe was considered most appropriate, and Krabbe least appropriate, for NBS. MPS1 and MPS2 were overall considered favorably for screening, but MPS1 ranked higher, due to a perception of better efficacy of therapeutic options. Fabry and Gaucher diseases were viewed less favorably due to later age of onset. The themes identified in this study must be addressed by decision-makers in expanding NBS for LSDs and may be applied to many diseases being considered for NBS in the future.

Available only for authorised users

Abrams, L., Cronister, A., Brown, W. T., Tassone, F., Sherman, S. L., Finucane, B., . . . Berry-Kravis, E. (2012). Newborn, carrier, and early childhood screening recommendations for fragile X. Pediatrics, 130(6), 1126–1135. doi:https://doi.org/10.1542/peds.2012-0693 PubMedCrossRef

Acharya, K., & Schindler, A. (2013). Developmental and behavioral pedatricians’ attitudes toward screening Fragile X. American J of Intellectual and Dev Disabilities, 118(4), 284–293.CrossRef

Aldenhoven, M., Boelens, J. J., & de Koning, T. J. (2008). The clinical outcome of Hurler syndrome after stem cell transplantation. Biology of Blood and Marrow Transplantation, 14(5), 485–498. doi:https://doi.org/10.1016/j.bbmt.2008.01.009.PubMedCrossRef

Atherton, A., Doheny, D. O., Peck, D., Christensen, K., Smith, K., Manwaring, L., … Heese, B. A. (2015). Newborn screening for Fabry disease: Is the A143T allele a pathogenic mutaiton or a pseudodeficiency allele? Molecular Genetics and Metabolism, 114, S14–S15.CrossRef

Beck, M. (2010). Therapy for lysosomal storage disorders. IUBMB Life, 62(1), 33–40. doi:https://doi.org/10.1002/iub.284.PubMed

Boado, R. J., Hui, E. K., Lu, J. Z., Sumbria, R. K., & Pardridge, W. M. (2013). Blood–brain barrier molecular trojan horse enables imaging of brain uptake of radioiodinated recombinant protein in the rhesus monkey. Bioconjugate Chemistry, 24(10), 1741–1749.PubMedCrossRef

Boelens, J. J., Prasad, V. K., Tolar, J., Wynn, R. F., & Peters, C. (2010). Current international perspectives on hematopoietic stem cell transplantation for inherited metabolic disorders. Pediatric Clinics of North America, 57(1), 123–145. doi:https://doi.org/10.1016/j.pcl.2009.11.004.PubMedCrossRef

Bombard, Y., Miller, F. A., Hayeems, R., Avard, D., & Knoppers, B. M. (2010). Reconsidering reproductive benefit through newborn screening: a systematic review of guidelines on preconception, prenatal and newborn screening. European Journal of Human Genetics, 18(7), 751–760.PubMedPubMedCentralCrossRef

Broadstock, M., Michie, S., & Marteau, T. (2000). Psychological consequences of predictive genetic testing: a systematic review. European Journal of Human Genetics, 8(10), 731–738. doi:https://doi.org/10.1038/sj.ejhg.5200532.CrossRefPubMed

Civallero, G., Michelin, K., de Mari, J., Viapiana, M., Burin, M., Coelho, J., & Giugliani, R. (2006). Twelve different enzyme assays on dried-blood filter paper sample for detection of patients with selected inherited lysosomal storage diseases. Clinica Chimica Acta, 372, 98–102.CrossRef

Cyrus, A., Street, N., Quary, S., Kable, J., Kenneson, A., & Fernhoff, P. (2012). Clinic-based infant screening for Duchenne muscular dystrophy: a feasability study. PLOS Currents, 4, e4f99c5654147a.PubMedCentralCrossRef

de Ru, M., Bouwman, M., Wijburg, F., & van Zwieten, M. (2012). Experiences of parents and patients with the timing of Mucopolysaccharidosis type I (MPSI) diagnoses and its relevance to the ethical debate on newborn screening. Molecular Genetics and Metabolism, 107(3), 501–507.PubMedCrossRef

Desnick, R. J., Doheny, D. O., Chen, B., Yu, C., Nazarenko, I., Lee, B., … Kadirvel, S. (2015). Fabry disease: the alpha-galactosidase A (GLA) c.427G>A (A143T) mutation, effect of the 5′-10C>T polymorphism. Molecular Genetics and Metabolism , 114, S37.CrossRef

Duffner, P. K., Caggana, M., Orsini, J. J., Wenger, D. A., Patterson, M. C., Crosley, C. J., … Wasserstein, M. P. (2009). Newborn screening for Krabbe disease: the New York State model. Pediatric Neurology, 40(4), 245–252; discussion 253–245. doi:10.1016/j.pediatrneurol.2008.11.010PubMedCrossRef

Fletcher, J. M. (2006). Screening for lysosomal storage disorders--a clinical perspective. Journal of Inherited Metabolic Disease, 29(2–3), 405–408. doi:https://doi.org/10.1007/s10545-006-0246-7.PubMedCrossRef

Germain, D., Charrow, J., Desnick, R., Guffon, N., Kempf, J., Lachmann, R., … Wilcox, W. (2015). Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease. Journal of Medical Genetics, 52(5), 353–358.PubMedCrossRef

Giugliani, R., Federhen, A., Rojas, M. V., Vieira, T., Artigalas, O., Pinto, L. L., … Martins, A. M. (2010). Mucopolysaccharidosis I, II, and VI: Brief review and guidelines for treatment. Genetics and Molecular Biology, 33(4), 589–604. doi:10.1590/S1415-47572010005000093PubMedPubMedCentralCrossRef

Grosfeld, F. J., Lips, C. J., Beemer, F. A., van Spijker, H. G., Brouwers-Smalbraak, G. J., & ten Kroode, H. F. (1997). Psychological risks of genetically testing children for a hereditary cancer syndrome. Patient Education and Counseling, 32(1), 63–67.PubMedCrossRef

Guffon, N., Bertrand, Y., & Forest, I. (2009). Bone marrow transplantation in children with Hunter syndrome: outcome after 7 to 17 years. The Journal of Pediatrics, 154(5), 733–737.PubMedCrossRef

Hayes, I. M., Collins, V., Sahhar, M., Wraith, J. E., & Delatycki, M. B. (2007). Newborn screening for mucopolysaccharidosis: opinions of patients and their families. Clinical Genetics, 71(5), 446–450.PubMedCrossRef

Hennink, M., Hutter, I., & Bailey, A. (2011). Qualitative research methods. London: SAGE Publications, Ltd.

Hoefsloot, L. H., van der Ploeg, A. T., Kroos, M. A., Hoogeveen-Westerveld, M., Oostra, B. A., & Reuser, A. J. (1990). Adult and infantile glycogenosis type II in one family, explained by allelic diversity. American Journal of Medical Genetics, 46, 45–52.

Hopkins, P., Campbell, C., Klug, T., Rogers, S., Raburn-Miller, J., & Kiesling, J. (2015). Lysosomal storage disorder screening implementation: findings from the first six months of full population pilot testing in Missouri. The Journal of Pediatrics, 166(1), 172–177.PubMedCrossRef

Kemper, A. R., Knapp, A. A., Green, N. S., Comeau, A. M., Metterville, D. R., & Perrin, J. M. (2010). Weighing the evidence for newborn screening for early-infantile Krabbe disease. Genetics in Medicine, 12(9), 539–543.PubMedCrossRef

Kishnani, P. S., Corzo, D., M., N., Byrne, B., Mandel, H., Hwu, W. L., … Wraith, J. E. (2007). Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology, 68(2), 99–109.

Kishnani, P. S., Corzo, D., Leslie, N. D., Gruskin, D., Van der Ploeg, A., Clancy, J. P., … Mandel, H. (2009). Early treatment with alglucosidase alpha prolongs long-term survival of infants with Pompe disease. Pediatric Research, 66(3), 329–335.PubMedPubMedCentralCrossRef

Kwon, J. M., & Steiner, R. D. (2012). I’m fine; I’m just waiting for my disease”: the new and growing class of presymptomatic patients. Neurology, 77, 522–523.CrossRef

Laney, D., & Fernhoff, P. (2008). Diagnosis of Fabry disease via analysis of family history. Journal of Genetic Counseling, 17(1), 79–83.PubMedCrossRef

Massie, J., Curnow, L., Gaffney, L., Carlin, J., & Francis, I. (2011). Declining prevalence of cystic fibrosis since the introduction of newborn screening. Archives of Disease in Childhood, 96(6), e1.CrossRef

Matern, D., Oglesbee, D., & Tortorelli, S. (2013). Newborn screening for lysosomal storage disorders and other neuronopathic conditions. Developmental Disabilities Research Reviews, 17(3), 247–253.PubMedPubMedCentralCrossRef

McClaren, B., Aitken, M., Massie, J., Amor, D., Ukoumunne, O., & Metcalfe, S. (2013). Cascade carrier testing after a child is diagnosed with cystic fibrosis through newborn screening: investigating why most relatives do not have testing. Genetics in Medicine, 15(7), 533–540.PubMedCrossRef

Mechtler, T., Stary, S., Metz, T., De Jesús, V., Greber-Platzer, S., Pollak, A., … Kasper, D. (2012). Neonatal screening for lysosomal storage disorders: feasibility and incidence from a nationwide study in Austria. The Lancet, 379, 335–341.CrossRef

Miekle, P., Grasby, D., Dean, C., Lang, D., Bockmann, M., Whittle, A., … Hopwood, J. (2006). Newborn screening for lysosomal storage disorders. Molecular Genetics and Metabolism , 88, 307–314.PubMedCrossRef

Muenzer, J., Wraith, J. E., & Clarke, L. A. (2009). International consensus panel on management and treatment of mucopolysaccharidosis I. Mucopolysaccharidosis I: management and treatment guidelines. Pediatrics, 123(1), 19–29.PubMedCrossRef

Muenzer, J., Hendriksz, C. J., Stein, M. B., Fan, Z., Kearney, S., Horton, J., … Barbier, A. J. (2015). Long-term biomarker and cognitive follow-up of children with Hunter syndrome receiving intrathecal enzyme replacement therapy. Molecular Genetics and Metabolism, 114, S83.CrossRef

O’Neill, S. C., Rini, C., Goldsmith, R., Valdimarsdottir, H., Cohen, L. H., & Schwartz, M. D. (2009). Distress among women receiving uninformative BRCA1/2 results: 12-month outcomes. Psychooncology, 18(10), 1088–1096.PubMedPubMedCentralCrossRef

Peters, C., Balthazor, M., & Shapiro, E. G. (1996). Outcome of unrelated donor bone marrow transplantation in 40 children with Hurler syndrome. Blood, 87, 4864–4902.CrossRef

Peters, C., Shapiro, E. G., & Anderson, J. (1998). Hurler syndrome. Outcome of HLA-genotypically identical sibling and HLA-haploidentical related donor bone marrow transplantation in fifty-four children. Blood, 91, 2601–2608.PubMedCrossRef

Pisani, A., Visciano, B., Roux, G. D., Sabbatini, M., Porto, C., Parenti, G., & Imbriaco, M. (2012). Enzyme replacement therapy in patients with Fabry disease: state of the art and review of the literature. Molecular Genetics and Metabolism, 107(3), 267–275.PubMedCrossRef

Plass, A. M., Van El, C. G., Pieters, T., & Cornel, M. C. (2010). Neonatal screening for treatable and untreatable disorders: prospective parents’ opinions. Pediatrics, 125(1), e99–e106.PubMedCrossRef

Ross, L. (2012). Newborn screening for lysosomal storage diseases: an ethical and policy analysis. Journal of Inherited Metabolic Disease, 35(4), 127–134.CrossRef

Ross, L. F., & Acharya, K. (2008). Policy considerations in designing a Fragile X screening program. Genetics in Medicine, 10(10), 711–713.PubMedPubMedCentralCrossRef

Ross, L. F., & Acharya, K. (2009). Fragile X screening: views of genetic health professionals. American Journal of Medical Genetics. Part A, 15(4), 626–632.

Ross, L. F., & Waggoner, D. J. (2012). Parents: critical stakeholders in expanding newborn screening. The Journal of Pediatrics, 161(3), 385–389.PubMedCrossRef

Ross, L. F., Saal, H. M., David, H. L., & Anderson, R. R. (2013). Technical report: ethical and policy issues in genetic testing and screening in children. ACMG Policy Statement. Genetics in Medicine, 15(3), 234–245.PubMedCrossRef

Schweitzer-Krantz, S. (2003). Early diagnosis of inherited metabolic disorders towards improving outcome: the controversial issue of galactosaemia. European Journal of Pediatrics, 162(1), S50–S53.PubMedCrossRef

Terlato, N. J., & Cox, G. F. (2003). Can mucopolysaccharidosis type I disease severity be predicted based on a patient’s genotype? A comprehensive review of the literature. Genetics in Medicine, 5, 286–294.PubMedCrossRef

Tluczek, A., Mischler, E. H., Farrell, P. M., Fost, N., Peterson, N. M., Carey, P., … McCarthy, C. (1992). Parents’ knowledge of neonatal screening and response to false-positive Cystic Fibrosis testing. The Developmental and Behavioral Pediatrics, 13, 181–186.CrossRef

van El, C. G., Rigter, T., Reuser, A. J., Van der Ploeg, A., Weinreich, S. S., & Cornel, M. C. (2014). Newborn screening for Pompe disease? A qualitative study exploring professional views. BMC Pediatrics, 14(203). doi:https://doi.org/10.1186/1471-2431-14-203.

van Maldegem, B. T., Wanders, R. J., & Wijburg, F. A. (2010). Clinical aspects of short-chain acyl-CoA dehydrogenase deficiency. Journal of Inherited Metabolic Disease, 33(5), 507–511.PubMedPubMedCentralCrossRef

Warnock, D. G., Ortiz, A., Mauer, M., Linthorst, G. E., Oliveira, J. P., Serra, A. L., … Wanner, C. (2012). Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation. Nephrology Dialysis Transplantation, 27(3), 1042–1049.PubMedCentralCrossRef

Weinreich, S. S., Rigter, T., van El, C. G., Dondorp, W. J., Kostense, P. J., Van der Ploeg, A., … Hagemans, M. L. C. (2012). Public support for neonatal screening for Pompe disease, a broad-phenotype condition. Orphanet Journal of Rare Diseases, 7(15). doi:https://doi.org/10.1186/1750-1172-7-15.PubMedPubMedCentralCrossRef

Wraith, J. E., Scarpa, M., Beck, M., Bodamer, O. A., De Meirleir, L., Guffon, N., … Zeman, J. (2008). Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy. European Journal of Pediatrics , 167(3), 267–277.PubMedPubMedCentralCrossRef

Yang, C.-F., Liu, H.-C., Hsu, T.-R., Tsai, F.-C., Chiang, S.-F., Chiang, C.-C., … Niu, D.-M. (2013). A large-scale nationwide newborn screening program for Pompe disease in Taiwan: towards effective diagnosis and treatment. American Journal of Medical Genetics Part A , 164A, 54–61.CrossRef

Title: Newborn Screening for Lysosomal Storage Disorders: Views of Genetic Healthcare Providers
Authors: Emily C. Lisi
Shawn E. McCandless
Publication date: 01-04-2016
Publisher: Springer US
Published in: Journal of Genetic Counseling / Issue 2/2016
Print ISSN: 1059-7700
Electronic ISSN: 1573-3599
DOI: https://doi.org/10.1007/s10897-015-9879-8

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Newborn Screening for Lysosomal Storage Disorders: Views of Genetic Healthcare Providers

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2016

Attitudes Toward Genetic Testing for Celiac Disease

Impact of Genetic Counseling in Women with a Family History of Breast Cancer in Italy

Acceptability of, and Information Needs Regarding, Next-Generation Sequencing in People Tested for Hereditary Cancer: A Qualitative Study

Parents’ Experience with Pediatric Microarray: Transferrable Lessons in the Era of Genomic Counseling

Genetic Counseling Supervisors’ Self-Efficacy for Select Clinical Supervision Competencies

Reproductive Health CHOICES for Young Adults with Sickle Cell Disease or Trait: Randomized Controlled Trial Outcomes over Two Years